Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
OHSU Knight Cancer Institute
Stanford University
MedSIR
University of Texas Southwestern Medical Center
Northwestern University
The Methodist Hospital Research Institute
University of Washington